PERFORM = Pentaglobin® Registry For Outcome Report and Monitoring

Overview

International registry on the use of Pentaglobin® in patients with severe bacterial infections; multicentric, international registry, non-interventional trial

Aim of the Pentaglobin® registry of adult critically ill patients with severe infections is primarily to assess the effects of IVIgAM on the aforementioned outcome parameters and its side effects under real-life conditions based on a prospective, high-quality data documentation * Age ≥ 18 years * Diagnosis of severe bacterial infection * Pentaglobin® use * signed informed consent for data collection Exclusion criteria None Primary endpoints * Comparison APACHE II and SAPS II predicted mortality vs. observed hospital mortality and * Difference in SOFA scores, baseline vs. posttreatment (24 h after last application) assessment Secondary endpoints * In-hospital mortality total and in subgroups according to baseline IgM serum levels (\< 80 mg/dL vs. ≥ 80 mg/dL) and baseline CRP (\< 70 mg/L vs. ≥ 70 mg/L) * Change in MOF score from the day before treatment start till 24 h after last application of Pentaglobin * Course of laboratory markers (concentration-difference): CRP, procalcitonin, IL-6, IgM, IgA, IgG before treatment start till 24 h after last application as far as available in the centers * Duration of ICU stay (days) * Duration of hospital stay (days) * Time from onset of severe bacterial infection to start of treatment

Conditions

Eligibility

Locations (12)

Outcomes